Literature DB >> 32329852

CircRNA EPB41L2 inhibits tumorigenicity of lung adenocarcinoma through regulating CDH4 by miR-211-5p.

S-J Zhang1, J Ma, J-C Wu, Z-Z Hao, Y-N Zhang, Y-J Zhang.   

Abstract

OBJECTIVE: Circular RNAs (circRNAs) can make contributions to cell proliferation, migration and invasion in lung adenocarcinoma (LUAD). Circ_Band 4.1-like protein 2 (circ_EPB41L2) was found to have anti-tumor roles in lung cancer. Herein, we investigated the roles of circ_EPB41L2 in LUAD tumorigenicity. PATIENTS AND METHODS: The expression of circ_EPB41L2, microRNA (miR)-211-5p, and Cadherin-4 (CDH4) was measured using quantitative real-time polymerase chain reaction. Western blot was used to detect the levels of CDH4, Ki67, and E-cadherin. Cell proliferation, migration and invasion were examined using 3-(4,5)-dimethylthiazol(-z-y1)-3,5-di-phenyltetrazoliumbromide (MTT) assay and transwell assay, respectively. The interaction between miR-211-5p and circ_EPB41L2 or CDH4 was confirmed by Dual-Luciferase reporter assay. In vivo experiments were conducted using the murine xenograft model.
RESULTS: Circ_EPB41L2 and CDH4 were down-regulated in LUAD tissues and cell lines. Overexpressed circ_EPB41L2 or CDH4 acted as a suppressor in the LUAD cell proliferation, invasion and migration in vitro. MiR-211-5p directly bound to circRNA_EPB41L2 and CDH4 3'-UTR, and circ_EPB41L2 indirectly regulated CDH4 expression by binding to miR-211-5p in LUAD cells. Furthermore, rescue assay showed circ_EPB41L2 played a protective role by repressing proliferation, migration and invasion through regulating CDH4 and miR-211-5p in LUAD cells. Besides, in vivo experiments indicated circ_EPB41L2 overexpression also inhibited tumor growth through regulating miR-211-5p and CDH4.
CONCLUSIONS: Circ_EPB41L2 functioned as a tumor suppressor to inhibit the proliferation, migration and invasion through regulating CDH4 by miR-211-5p in LUAD cells, suggesting a new understanding on the tumorigenesis of LUAD and novel molecular therapeutic targets.

Entities:  

Year:  2020        PMID: 32329852     DOI: 10.26355/eurrev_202004_20839

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  7 in total

1.  Identification of a Novel circ_0010235/miR-1249-3p/HOXA13 Axis in Lung Adenocarcinoma.

Authors:  Jiancheng Liu; Zejun Fu
Journal:  Biochem Genet       Date:  2022-01-25       Impact factor: 2.220

2.  Circ-AASDH functions as the progression of early stage lung adenocarcinoma by targeting miR-140-3p to activate E2F7 expression.

Authors:  Yuanyong Wang; Yang Wo; Tong Lu; Xiao Sun; Ao Liu; Yanting Dong; Wenxing Du; Wenhao Su; Zhangfeng Huang; Wenjie Jiao
Journal:  Transl Lung Cancer Res       Date:  2021-01

3.  Circular RNA CircEPB41L2 Functions as Tumor Suppressor in Hepatocellular Carcinoma Through Sponging miR-590-5p.

Authors:  Feng Chen; Lei He; Liman Qiu; Yang Zhou; Zhenli Li; Geng Chen; Fuli Xin; Xiuqing Dong; Haipo Xu; Gaoxiong Wang; Jingfeng Liu; Zhixiong Cai
Journal:  Cancer Manag Res       Date:  2021-04-01       Impact factor: 3.989

4.  Identification of Differentially Expressed Circular RNAs as miRNA Sponges in Lung Adenocarcinoma.

Authors:  Yuechao Liu; Xin Wang; Lulu Bi; Hongbo Huo; Shi Yan; Yimeng Cui; Yaowen Cui; Ruixue Gu; Dexin Jia; Shuai Zhang; Li Cai; Xiaomei Li; Ying Xing
Journal:  J Oncol       Date:  2021-09-10       Impact factor: 4.375

5.  A Novel Intercellular Communication-Associated Gene Signature for Prognostic Prediction and Clinical Value in Patients With Lung Adenocarcinoma.

Authors:  Qin-Yu Zhao; Le-Ping Liu; Lu Lu; Rong Gui; Yan-Wei Luo
Journal:  Front Genet       Date:  2021-08-23       Impact factor: 4.599

6.  MiR-211-5p Inhibits the Biological Behaviors of Colorectal Cancer via SPARC-Related Growth Factor Pathways.

Authors:  Xiaoyu Wu; Yu Chen; Ya Zhu; Facai Cui
Journal:  J Cancer       Date:  2022-03-21       Impact factor: 4.207

Review 7.  Circular RNAs in Lung Cancer: Recent Advances and Future Perspectives.

Authors:  Huan-Huan Chen; Tie-Ning Zhang; Qi-Jun Wu; Xin-Mei Huang; Yu-Hong Zhao
Journal:  Front Oncol       Date:  2021-07-06       Impact factor: 6.244

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.